Citadel Advisors
CGON icon

Citadel Advisors’s CG Oncology CGON Stock Holding History

Citadel Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.7M Sell
172,815
-508,371
-75% -$28.8M ﹤0.01% 3032
2025
Q4 		$28.3M Buy
681,186
+442,414
+185% +$18.3M ﹤0.01% 1965
2025
Q3 		$9.62M Buy
238,772
+63,519
+36% +$1.85M ﹤0.01% 3336
2025
Q2 		$4.56M Sell
175,253
-963,665
-85% -$23.2M ﹤0.01% 4274
2025
Q1 		$27.9M Sell
1,138,918
-30,335
-3% -$853K 0.01% 1672
2024
Q4 		$33.5M Buy
1,169,253
+847,890
+264% +$29M 0.01% 1635
2024
Q3 		$12.1M Sell
321,363
-170,331
-35% -$5.97M ﹤0.01% 2631
2024
Q2 		$15.5M Buy
491,694
+215,233
+78% +$7.46M ﹤0.01% 2271
2024
Q1 		$12.1M Buy
+276,461
New +$11.3M ﹤0.01% 2673

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's CGON Position: Q1 2026 in Review

Citadel Advisors reduced its CG Oncology (CGON) stake by 75% in Q1 2026, selling an estimated $28.8M and leaving 172,815 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3032.

Citadel Advisors first reported a position in CGON in Q1 2024 and has held it in 9 quarters since. The position peaked at $33.5M in Q4 2024. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Citadel Advisors held 172,815 shares of CG Oncology worth $11.7M as of Q1 2026.
  • Citadel Advisors sold 508,371 CG Oncology shares in Q1 2026, an estimated $28.8M.
  • CG Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3032 holding.
  • Citadel Advisors first reported a position in CG Oncology in Q1 2024 and has held it in 9 quarters since.
  • Citadel Advisors's CG Oncology position peaked at $33.5M in Q4 2024.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.